ホーム/MCK

Public research page

Market data comes from the live feed. The company research below uses verified public sources, but it is not a real-time personalized AI conclusion.

Analyze MCK in workspace
MCKNYSE/health care

McKesson Corporation

$812.28Up+6,32 (+0,78%)
Research reviewed: 2026年7月12日 00:00 UTC
Research overview3-month price contextInvestment thesisKey catalystsLatest earnings researchRecent newsData and research sources

Research overview

McKesson Corporation operates in Health Care Distributors within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.

Eröffnung
812,87
Hoch
822,38
Tief
806,24
Marktkapitalisierung
95,1 Mrd.
KGV
21.18
52-Wochen-Hoch
--
Dividende
0.410%
Quartalsdividende
--

3-month price context

直近3か月の推移を表示し、フル調査ワークスペースに進む前に短期構造を把握できます。

Investment thesis

Base case
Growth in complex medicines can increase distribution, provider-services and data demand. The base case remains conditional on customer concentration staying manageable.
Bull case
Growth in complex medicines can increase distribution, provider-services and data demand. The US Oncology Network and related services can deepen relationships with community practices and manufacturers. Strong cash conversion can fund repurchases and targeted investment in higher-growth health platforms.
Bear case
Large pharmacy and manufacturer relationships can create contract-renewal and pricing leverage risk. Reimbursement, pricing and distribution reforms can alter volumes, working capital and service economics. Controlled-substance obligations and healthcare compliance failures can create litigation and remediation costs.
Thesis invalidation
Reassess the thesis if large pharmacy and manufacturer relationships can create contract-renewal and pricing leverage risk.

Key catalysts

  • Specialty distribution

    Growth in complex medicines can increase distribution, provider-services and data demand.

  • Oncology ecosystem

    The US Oncology Network and related services can deepen relationships with community practices and manufacturers.

  • Capital allocation

    Strong cash conversion can fund repurchases and targeted investment in higher-growth health platforms.

Principal risks

  • Customer concentration

    Large pharmacy and manufacturer relationships can create contract-renewal and pricing leverage risk.

  • Drug-policy change

    Reimbursement, pricing and distribution reforms can alter volumes, working capital and service economics.

  • Legal and compliance

    Controlled-substance obligations and healthcare compliance failures can create litigation and remediation costs.

Latest earnings research

FY2026 Q4

McKesson's fiscal fourth-quarter 2026 update reflected resilient pharmaceutical distribution, oncology-platform growth and continued portfolio focus, supported by cash generation and disciplined capital allocation.

Valuation interpretation

  • Distribution scale supports durable cash flow, while oncology and specialty services determine the mix-improvement opportunity.
  • Thin distribution margins require valuation discipline around working capital, customer concentration and policy change.

Peer research

ABBVJNJLLY

Recent news

Zacks · vor 9 Stunden

5 Medical Supply Stocks to Buy Amid Strong Industry Tailwinds

Simply Wall St. · vorgestern

McKesson (MCK) Falls After CEO Share Sale, Is The 14% Discount Enough?

Simply Wall St. · vor 3 Tagen

Can McKesson (MCK) Stay Cheap After A 338% Five Year Run?

Simply Wall St. · vor 3 Tagen

McKesson (MCK) CEO Sells Shares As Company Names A New Strategy Chief

StockStory · vor 4 Tagen

McKesson (MCK) Stock Trades Down, Here Is Why

Zacks · vor 4 Tagen

Should You Retain CAH Stock After Removal From Several Russell Indices?

Data and research sources

Research updated: 2026年7月12日 00:00 UTC
3 verified sources
McKesson Reports Fiscal 2026 Fourth-Quarter ResultsMcKesson Corporation · earningsVerified

Fetched: 2026/7/12 0:00:00 UTC

Published: 2026/5/7 0:00:00

Open original source
McKesson Corporation Investor RelationsMcKesson Corporation · companyVerified

Fetched: 2026/7/12 0:00:00 UTC

Open original source
McKesson SEC filings and company factsU.S. Securities and Exchange Commission · filingVerified

Fetched: 2026/7/12 0:00:00 UTC

Published: 2026/5/7 0:00:00

Open original source

Continue in the research workspace

Keep MCK in context, run a multi-agent analysis, and monitor thesis changes.

Analyze MCK free

リサーチシステム全体を見る

各段階には固有の役割があり、次の段階で検証可能な成果を残します。

リサーチ手法市場レポートを読む銘柄を探す

Continue researching this stock

市場アナリスト

市場アナリスト は コアリサーチ の中で 観察 段階を専門に担い、後続判断の前提を整える役割です。

ファンダメンタルズアナリスト

ファンダメンタルズアナリスト は コアリサーチ の中で 観察 段階を専門に担い、後続判断の前提を整える役割です。

ニュースアナリスト

ニュースアナリスト は コアリサーチ の中で 観察 段階を専門に担い、後続判断の前提を整える役割です。

リスクマネージャー

リスクマネージャー は リスクと監視 の中で 監視 段階を専門に担い、後続判断の前提を整える役割です。